Nektar Therapeutics 8-K filings

Nektar Therapeutics announced its second quarter 2024 financial results, highlighting progress in clinical trials and a cash runway extending into the third quarter of 2026.

Nektar Therapeutics held its annual stockholders meeting on June 5, 2024, where directors were elected, an incentive plan was amended, and the company's accounting firm was ratified.

Nektar Therapeutics announced its first quarter 2024 financial results, highlighting a decrease in operating costs and advancements in its immunology and inflammation pipeline.

Nektar Therapeutics has regained compliance with Nasdaq's minimum bid price requirement after its stock price closed above $1.00 for ten consecutive days.

Nektar Therapeutics amended a royalty agreement for $15 million and reported a reduced net loss for 2023, alongside progress in its immunology pipeline.

Nektar Therapeutics has entered into a securities purchase agreement for a $30 million private placement of a pre-funded warrant to TCG Crossover Fund II, L.P.

Nektar Therapeutics has repurchased 8,284,600 shares from Bristol-Myers Squibb for $3 million, reducing its outstanding shares by approximately 4.34%.